Tyra Biosciences Inc (TYRA)
17.35
-0.41
(-2.31%)
USD |
NASDAQ |
May 10, 16:00
17.36
+0.02
(+0.09%)
After-Hours: 20:00
Tyra Biosciences Cash from Financing (TTM): 1.537M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.537M |
| September 30, 2023 | 1.216M |
| June 30, 2023 | 1.113M |
| March 31, 2023 | 0.77M |
| December 31, 2022 | 0.632M |
| Date | Value |
|---|---|
| September 30, 2022 | -0.879M |
| June 30, 2022 | 182.19M |
| March 31, 2022 | 181.43M |
| December 31, 2021 | 311.35M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.879M
Minimum
Sep 2022
311.35M
Maximum
Dec 2021
75.48M
Average
1.216M
Median
Sep 2023
Cash from Financing (TTM) Benchmarks
| NovaBay Pharmaceuticals Inc | 1.91M |
| Palatin Technologies Inc | 5.553M |
| iBio Inc | 10.68M |
| Theriva Biologics Inc | 0.625M |
| Oragenics Inc | 0.2839M |